Endo Pharmaceuticals Solutions (IDEV) Inactive
Filed: 14 Jan 09, 12:00am
      1 Indevus – A Unique Growth Opportunity Time Pain Pain Specialty Specialty Generics Generics Pelvic Pelvic Disease Disease Exhibit (a)(5)(L) |
 2 Tender Offer This communication is provided for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any shares of Indevus common stock. The solicitation and the offer to purchase shares of Indevus common stock is being made pursuant to a tender offer statement on Schedule TO (including an offer to purchase, a letter of transmittal and related materials) that Endo and BTB Purchaser Inc. filed with the SEC on January 7, 2009. Indevus also filed a solicitation/recommendation statement on Schedule 14D-9 with the SEC with respect to the tender offer on January 7, 2009. Investors and Indevus stockholders are urged to read both the tender offer statement (and related materials), as it may be amended from time to time, and the solicitation/recommendation statement, as it may be amended from time to time, because they contain important information. Investors and security holders may obtain a free copy of these statements and other documents filed by Endo, BTB Purchaser Inc., Indevus and their affiliates with the SEC at the website maintained by the SEC at www.sec.gov. In addition, the tender offer statement and related materials may be obtained for free at Endo's website at www.endo.com or by directing such requests to Endo (Investor Relations) at (610) 459-7158, IR@endo.com, or by calling MacKenzie Partners, the information agent for the offer toll-free at (800) 322-2885. The solicitation/recommendation statement and such other documents may be obtained by directing such requests to Indevus (Investor Relations) at (781) 402-340, RDeCarlo@indevus.com. |
 3 Transaction Overview • All cash tender offer for 100% of IDEV stock at $4.50 per share, plus the right to receive contingent payments • Two contingent cash payments (approximately $267 M) – NEBIDO® (up to $2.00 per IDEV share) • $2 payable upon regulatory approval with unrestrictive labeling -OR- • $1 payable upon regulatory approval within three years with restrictive labeling plus; • $1 payable upon achievement of $125 M in annual net sales in first five years post launch – Octreotide implant approval within four years ($1.00 per IDEV share) • Upfront cash utilized in transaction: ~$370 M – 40% of cash, cash equivalents & marketable securities (as of 9/30/08) |
 4 Indevus Company Overview Specialty pharmaceutical company focused on urology and endocrinology Five marketed products Well differentiated Strong growth potential Efficient sales & marketing (100 reps) Specialized manufacturing Late-stage pipeline 5 products in mid- to late-stage clinical development 2 products currently seeking regulatory approval Unique and proprietary drug delivery technology |
 5 Indevus Product Pipeline |
 6 Small, Soft, Hydrogel Subcutaneous Implant Well-controlled, Platform-based Technology Continuous, Steady-state drug delivery Highly biocompatible Proprietary manufacturing process in Cranbury, NJ Market Validated; Approved- FDA, EU, South America, Asia VANTAS®, Supprelin® LA Extensive safety experience (>50,000 implants to date) Controlled Diffusion Through Wall D R U G HYDRON® Polymer Technology Implant Overview |
 7 Value of Indevus to Endo • Pain franchise provides foundation for combined entity • Urology represents market with large growth opportunity • Indevus provides near-term revenue stream • Indevus broadens pipeline and provides platform technology • Indevus supports Endo’s expanded vision |
 8 Indevus Revenue History* (Fiscal year)* *Indevus’ fiscal year ends on 9/30 ($000’s) |